Posts Tagged ‘Treprostinil’

Additionally, the base-case analysis did not include the cost of pain management for each treatment. The actual cost of pain management could not be captured accurately and, therefore, it did not seem sensible to include the assumption in our base-case analysis, especially from the MoH perspective.

However, various limitations were present in that study, such as the assumption of equal hospital resource utilization between the two therapies and the use of average doses that are out of line with current dose studies. In addition, the decision analysis performed did not include the cost to treat sepsis, as indicated in both the […]

The present economic evaluation was performed to provide the decision makers of various drug plans with a pharmacoeconomic profile of treprostinil in the treatment of patients with severe PAH (NYHA class III or IV). In the base-case analysis, the first three years of treating the cohort with treprostinil resulted in a cost savings of $2,610,642 […]

Sensitivity analyses One-way sensitivity analyses were performed to determine the impact of varying specific parameters. The sensitivity of the model to the dose adjustment factor was tested by varying the dose ratio while maintaining all other variables constant. The cost savings of treprostinil were expected to be reduced as the dose ratio approached 1.09:1. Results […]

Base-case and sensitivity parameters, including the probability distributions used in the multivariate analyses, are presented in Table 4. The unit price of treprostinil was $45/mg for all base-case analyses and the dose adjustment factor was maintained at 0.82:1 (ratio of treprostinil to epoprostenol). Table 5 presents the total expected costs of each therapy categorized by […]

The rehospitalization ALOS for treprostinil (10.2 days) was determined by multiplying the ALOS for epoprostenol (15 days) by the probability of rehospitalization for treprostinil (0.68). The weighting of 0.50 for ICU time and for general ward time was based on clinical expertise. buy flovent inhaler Resource use per septic episode was determined from the literature […]

The time spent on training patients was determined to be a single 15 min session for treprostinil and five daily 15 min sessions for epoprostenol. buy asthma inhaler To determine the total cost of hospitalization, the average length of stay (ALOS) in the hospital was multiplied by the average daily hospital cost. The ALOS reported […]

Hospitalization rates and utilization were determined from the literature. Each listed reference presented data from several sources. Costs varied slightly according to the source; however, the valuations were similar among all reported resources. Epoprostenol use, because of its route of infusion, puts patients at risk for sepsis and line infections. McLaughlin et al reported a […]